These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11855661)

  • 1. Antiplatelet therapy in acute coronary syndromes without persistent ST-segment elevation.
    Jain D; Katus HA; Richardt G
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):423-36. PubMed ID: 11855661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
    Ault KA; Cannon CP; Mitchell J; McCahan J; Tracy RP; Novotny WF; Reimann JD; Braunwald E
    J Am Coll Cardiol; 1999 Mar; 33(3):634-9. PubMed ID: 10080462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiplatelet therapy in acute coronary syndromes without ST segment elevation].
    Umman B
    Anadolu Kardiyol Derg; 2006 Apr; 6 Suppl 1():13-9. PubMed ID: 16613770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes.
    Cox D; Smith R; Quinn M; Theroux P; Crean P; Fitzgerald DJ
    J Am Coll Cardiol; 2000 Nov; 36(5):1514-9. PubMed ID: 11079651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].
    Kakuta T; Kishi Y; Numano F
    Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department.
    Hoekstra J
    J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
    Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
    Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes.
    Tricoci P; Newby LK; Kandzari DE; Harrington RA
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
    Silva MA; Gandhi PJ
    J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing acute coronary syndrome: evidence-based approaches.
    Spinler SA
    Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa inhibitor therapy in non-ST segment elevation acute coronary syndromes.
    Elmouchi DA; Bates ER
    Minerva Cardioangiol; 2003 Oct; 51(5):547-60. PubMed ID: 14551523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings.
    Kleiman NS; Lincoff AM; Ohman EM; Harrington RA
    Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S32-42. PubMed ID: 9778086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.
    Antman EM
    Am Heart J; 2003 Oct; 146(4 Suppl):S18-22. PubMed ID: 14564302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.